29.60

0.54% 0.16

After Hours: 29.60

Mbx Biosciences Inc (MBX)

Overview News Price History Discussions Forecast

Mbx Biosciences Inc stock is traded at $29.60, with a volume of 312.73K. It is up +0.54% in the last 24 hours and down -10.28% over the past month. MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

Previous Close:

$29.44

Open:

$29.8

24h Volume:

312.73K

Relative Volume:

0.58

Market Cap:

$1.41B

Revenue:

Net Income/Loss:

$-86.97M

P/E Ratio:

-12.24

EPS:

-2.4189

Net Cash Flow:

$-81.88M

1W Performance:

+1.93%

1M Performance:

-10.28%

6M Performance:

+31.26%

1Y Performance:

+145.24%

1-Day Range:

$28.82

$30.64

1-Week Range:

$27.56

$32.03

52-Week Range:

$9.43

$44.89

Mbx Biosciences Inc Stock (MBX) Company Profile

Name

Mbx Biosciences Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(317) 989-3100

Address

11711 N. MERIDIAN STREET, CARMEL

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

MBX's Discussions on Twitter

Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBX Mbx Biosciences Inc	29.60	1.40B	0	-86.97M	-81.88M	-2.4189
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Overweight
Dec-04-25	Initiated	Goldman	Sell
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy
Aug-15-25	Resumed	Jefferies	Buy
Aug-05-25	Initiated	Mizuho	Outperform
Jul-16-25	Initiated	Oppenheimer	Outperform
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	JP Morgan	Overweight
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Stifel	Buy

View All

Mbx Biosciences Inc Stock (MBX) Latest News

May 04, 2026

MBX Biosciences (NASDAQ: MBX) director awarded RSUs and 74,249 stock options - Stock Titan

May 04, 2026

May 01, 2026

MBX (MBX) Rule 144: Bartram sold 21,484 shares; Fidelity lists 5,000 - Stock Titan

May 01, 2026

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) - The Globe and Mail

May 01, 2026

Apr 28, 2026

MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 28, 2026

Apr 27, 2026

BlackRock (MBX) files Schedule 13G/A showing 4.8% ownership - Stock Titan

Apr 27, 2026

MBX Biosciences stock down on pricing upsized public offering at $18.00 per share - MSN

Apr 27, 2026

Apr 26, 2026

Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN

Apr 26, 2026

A Look At MBX Biosciences (MBX) Valuation After Its Recent Share Price Move - Sahm

Apr 26, 2026

Apr 24, 2026

MBX Biosciences (NASDAQ:MBX) Amid Evolving Biotech Trends - Kalkine Media

Apr 24, 2026

MBX Biosciences (NASDAQ:MBX) Trading Down 6.3%Should You Sell? - MarketBeat

Apr 24, 2026

Apr 23, 2026

Truist reiterates Buy on MBX Biosciences stock ahead of trial data By Investing.com - Investing.com South Africa

Apr 23, 2026

Truist reiterates Buy on MBX Biosciences stock ahead of trial data - Investing.com Australia

Apr 23, 2026

MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio - The Manila Times

Apr 23, 2026

MBX to detail obesity drug pipeline at May 11 online, in-person event - Stock Titan

Apr 23, 2026

Apr 22, 2026

MBX Biosciences Inc. beats EPS estimates by 20.4%Community Driven Stock Picks - Xã Châu Thành

Apr 22, 2026

MBX Biosciences (MBX) Stock Outlook | MBX Biosciences Inc. beats EPS estimates by 20.4%Dividend Growth - Xã Vĩnh Công

Apr 22, 2026